Other version: https://www.thieme-connect.com/DOI/DOI?10.1055/s-2005-918556
Highlights
More informations
Home
Titles listToleranz von Coxiben bei Intoleranz gegenuber nicht-steroidalen Antirheumatika (NSAR)
Titles listToleranz von Coxiben bei Intoleranz gegenuber nicht-steroidalen Antirheumatika (NSAR)
Scientific Article
unige:29675 
 |
Toleranz von Coxiben bei Intoleranz gegenuber nicht-steroidalen Antirheumatika (NSAR) |
|
| Authors | ||
| Published in | Deutsche Medizinische Wochenschrift. 2005, vol. 130, no. 40, p. 2249-2252 | |
| Abstract | BACKGROUND AND OBJECTIVE: Non-steroidal anti-inflammatory drugs (NSAIDs) frequently cause pseudoallergic reactions. Recognition of two different prostaglandin synthase iso-enzymes led to the development of the so-called coxibs preferentially inhibiting cyclooxygenase-2. We studied tolerability of valdecoxib preferentially inhibitng cyclooxygenase-2 in patients with a history of intolerance to NSAIDs. PATIENTS AND METHODS: 41 patients (30 female, 11male, age 14-74 years) with a history of intolerance to NSAIDs underwent scratch tests with these drugs and valdecoxib, followed by oral challenge with valdecoxib (maximum single dose: 20 mg; cumulative dose: 35mg) in a double-blind, placebo-controlled manner. RESULTS: The history of intolerance to NSAID comprised urticaria as the leading symptom (n = 26), followed by angioedema (n = 11) and anaphylactoid shock (n = 4). 21 patients reported reactions to only one NSAID, 15 identified 2 different triggering drugs, and 5 patients showed reactions to 3 different NSAIDs. Acetylsalicylic acid (n = 20) and diclofenac (n = 12) were the most frequent causative drugs. Upon oral challenge with valdecoxib, one patient developed generalized urticaria within 30 minutes following the last dose of valdecoxib; symptoms resolved after i. v. injection of 2 mg clemastine and 250 mg prednisolone. All other patients tolerated the oral challenge without adverse effects. CONCLUSION: Our results are in line with previous studies suggesting that preferential cyclooxygenase-2-inhibitors may safely be used by patients with known intolerance to NSAIDs. | |
| Keywords | Administration, Oral — Adolescent — Adult — Aged — Anaphylaxis/chemically induced — Angioedema/chemically induced — Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects — Cyclooxygenase Inhibitors/administration & dosage/*adverse effects — Dose-Response Relationship, Drug — Double-Blind Method — *Drug Hypersensitivity — Female — Humans — Isoxazoles/administration & dosage/*adverse effects — Male — Middle Aged — Skin Tests — Sulfonamides/administration & dosage/*adverse effects — Urticaria/chemically induced | |
| Identifiers | PMID: 16208597 | |
| Full text | ||
| Citation (ISO format) | BOEHNCKE, Sandra, BOEHNCKE, Wolf-Henning. Toleranz von Coxiben bei Intoleranz gegenuber nicht-steroidalen Antirheumatika (NSAR). In: Deutsche Medizinische Wochenschrift, 2005, vol. 130, n° 40, p. 2249-2252. https://archive-ouverte.unige.ch/unige:29675 |
155 hits 
0 download 
Contact an author
Update